Push release MHRA approves GLP –1 receptor agonist semaglutide to cut back danger of serious coronary heart issues in obese or overweight Older people Semaglutide is the main weight loss drug authorised in the united kingdom like a preventative therapy for the people with founded heart problemsWe assistance eligible individuals to obtain patient